These data lay the groundwork for clinical testing of combination therapy that targets both MTOR gene expression (via restoration of IKAROS activity by CK2 inhibition), as well as direct inhibition of the mTOR protein (with rapamycin) in high-risk B-ALL. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.